10 June 2021. Taiwanese vaccine developer Medigen Vaccine Biologics Corporation (MVC) announced that it has completed the Phase II clinical trial for its COVID-19 vaccine candidate and the results of the trial meet safety and efficacy standards for an Emergency Use Authorization (EUA) set by the FDA.https://www.taiwannews.com.tw/en/news/4220165